Noble Capital Markets Served as Co-Manager to Eledon Pharmaceuticals (ELDN) in $85mm Follow-on Offering

October 29, 2024

Noble Capital Markets is pleased to announce its role as financial advisor in the completion of Eledon Pharmaceuticals’ recent underwritten offering of 18,356,173 shares of its common stock at a price of $3.65 per share and pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The transaction priced on October 29, 2024.

Eledon Pharmaceuticals, Inc. (ELDN) is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. Eledon’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. Eledon currently intends to use the net proceeds from this offering to advance its pipeline and for working capital and general corporate purposes.

This transaction highlights Noble’s ongoing commitment to providing strategic capital markets and advisory services to middle-market companies across a wide range of sectors. With deep sector knowledge and a client-first approach, Noble supports companies throughout their lifecycle — from capital formation to M&A execution.

For more information on Noble’s investment banking services, click here

For more information on this transaction, contact Nathan Cali @ ncali@noblecapitalmarkets.com